BioAge Labs, Inc.

NASDAQ:BIOA

Biotechnology

Healthcare
$4.77 +2.35%

+$0.47 today

Market cap
$179.59M
Beta
0.95
P/E (TTM)
-9.7
EPS (TTM)
-$2.12
52W Low $4.07High $24.00

Volume 0.64M

Average 0.46M

BIOA Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

BioAge Labs, Inc.NASDAQ: BIOA

Accounts Payables · Q1 FY2026 · quarter ended Mar 2026

Accounts payables declines year over year

Q1 FY2026 accounts payables of $326K fell 84.1% year over year, ahead of the -155.1% change in trailing-twelve-month accounts payables. Over 3 fiscal years it compounded at -7.4% a year.

Context

  • Accounts payables amounted to 8.8% of revenue in FY2025.
  • Accounts payables increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -84.1% holds above the trailing-twelve-month pace of -155.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$326K+114.1% QoQ
Last fiscal yearDec 2025
$788K+13033.3% YoY
LTMMar 2026
-$933K-155.1% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-84.1%——
1 year+13033.3%——
3-year CAGR-7.4%——
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
788K USD
Year-over-year change
+13033.3%
3-year CAGR
-7.4%

Accounts Payables vs competitors

How BIOA compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -155.1% is the 7th highest of 8, against a peer median of -67.8%.
  • Accounts payables amounts to 9.0% of revenue for BIOA, versus a peer median of 1.3%.
BIOA Competitors
Accounts Payables for BIOA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ACBAurora Cannabis Inc.LTM Mar 2026CA$8.05M CAD-158.1%+0.0%2.6%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$2.06M USD+115.0%——
EDITEditas Medicine, Inc.LTM Mar 2026$1.13M USD+32.3%—2.9%
BIOABioAge Labs, Inc.LTM Mar 2026$933K USD-155.1%-7.4%9.0%
LFCRLifecore Biomedical, Inc.LTM Mar 2026$734K USD——0.5%
CABACabaletta Bio, Inc.LTM Mar 2026$310K USD-132.7%——
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$232K USD-67.8%——
TKNOAlpha Teknova, Inc.LTM Mar 2026$60K USD+361.5%-6.3%0.1%
HUMAHumacyte, Inc.LTM Mar 2026$42K USD-102.6%—2.1%
CGCCanopy Growth CorporationLTM Mar 2026CA$0 CAD——0.0%
Peer median (excluding BIOA) —-67.8%-3.2%1.3%

Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(39.72M)(63.85M)(71.11M)(80.61M)
Depreciation & Amortization129K162K167K213K
Deferred Income Tax0000
Stock-Based Compensation2.54M3.02M6.98M11.69M
Change in Working Capital795K6.71M11.18M(11.83M)
Accounts Receivables000(769K)
Inventory0000
Accounts Payables994K(393K)6K788K
Other Working Capital(199K)7.1M11.17M(11.85M)
Other Non-Cash Items77K16.6M1.27M(1.1M)
Operating Cash Flow(36.18M)(37.36M)(51.52M)(81.63M)
Capital Expenditures(103K)(166K)(366K)(719K)
Acquisitions (Net)0000
Purchases of Investments0(100K)0(154.75M)
Sales of Investments00060.25M
Other Investing Activities0000
Investing Cash Flow(103K)(266K)(366K)(95.22M)
Debt Repayment2.5M35M(6M)(6M)
Common Stock Issued44K0221.62M17.87M
Common Stock Repurchased0000
Dividends Paid0000
Other Financing Activities(45K)(59K)(4.42M)(400K)
Financing Cash Flow2.5M34.94M381.2M11.47M
Effect of Forex Changes246K081K(87K)
Net Change in Cash(33.54M)(2.69M)329.39M(165.46M)
Free Cash Flow(36.28M)(37.53M)(51.89M)(82.35M)

BioAge Labs, Inc.

NASDAQ:BIOA

Intrinsic Alpha fair value

Locked

Current Price

$4.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.